SEARCH

SEARCH BY CITATION

References

  • 1
    Kramer H, Cao G, Dugas L, Luke A, Cooper R, Durazo-Arvizu R. Increasing BMI and waist circumference and prevalence of obesity among adults with type 2 diabetes: the National Health and Nutrition Examination Surveys. J Diabetes Complicat 2010; 24: 368374.
  • 2
    Rosenstock J, Riddle MC. Insulin therapy in type 2 diabetes. In: Cefalu WT, Gerich JE, LeRoith D eds. The CADRE Handbook of Diabetes Management. New York: Medical Information Press, 2004; 145168.
  • 3
    Dailey G, Rosenstock J, Moses RG, Ways K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004; 27: 23632368.
  • 4
    DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003; 289: 22542264.
  • 5
    Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193203.
  • 6
    Garg SK, Rosenstock J, Ways K. Optimized basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr Pract 2005; 11: 1117.
  • 7
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837853.
  • 8
    Purnell JQ, Weyer C. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat Endocrinol 2003; 2: 3347.
  • 9
    Freeman JS. Insulin analog therapy: improving the match with physiologic insulin secretion. J Am Osteopath Assoc 2009; 109: 2636.
  • 10
    Overmann H, Heinemann L. Injection-meal interval: recommendations of diabetologists and how patients handle it. Diabetes Res Clin Pract 1999; 43: 137142.
  • 11
    Becker RH, Frick AD. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet 2008; 47: 720.
  • 12
    Heise T, Nosek L, Spitzer H et al. Insulin glulisine: a faster onset of action compared with insulin lispro. Diabetes Obes Metab 2007; 9: 746753.
  • 13
    Apidra [prescribing information]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC, 2009. Available from URL: http://products.sanofi.us/apidra/apidra.pdf. Accessed 17 August 2011.
  • 14
    Bergenstal RM, Johnson M, Powers MA et al. Adjust to target in type 2 diabetes: comparison of a simple algorithm to carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care 2008; 35: 13051310.
  • 15
    Mitri J, Hamdy O. Diabetes medications and body weight. Expert Opin Drug Saf 2009; 8: 573584.
  • 16
    Hamdy O, Goebel-Fabbri A, Carver C et al. Why WAIT Program: A Novel Model for Diabetes Weight Management in Routine Clinical Practice. Obes Manage 2008; 4: 176183.
  • 17
    Bradley C, Speight J. Patient perceptions of diabetes and diabetes therapy: assessing quality of life. Diabetes Metab Res Rev 2002; 18(Suppl. 3): S64S69.